Inhibition of Protein <i>N-</i> Glycosylation Blocks SARS-CoV-2 Infection
Aitor Casas-Sánchez, Alessandra Romero-Ramirez, Eleanor Hargreaves, Cameron C. Ellis, Brian Grajeda, Igor L. Estevao, Edward I. Patterson, Grant L. Hughes, Igor C. Almeida, Tobias Zech, Álvaro Acosta-Serrano
Abstract
, including that of several variants. As new SARS-CoV-2 variants, with various degrees of resistance against current vaccines, are likely to continue appearing, halting virus glycosylation using repurposed human drugs could result in a complementary strategy to reducing the spread of COVID-19 worldwide.
Topics & Concepts
VirologyGlycosylationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakBiologySars virusMicrobiologyComputational biologyMedicineInfectious disease (medical specialty)DiseaseOutbreakGeneticsPathologyvaccines and immunoinformatics approachesGlycosylation and Glycoproteins ResearchMachine Learning in Bioinformatics